Decision Diagnostics Stock

Decision Diagnostics Equity

The The Equity of Decision Diagnostics (DECN) as of Aug 21, 2026 is 483,594.00 USD. In the previous year, The Equity was 87,584.00 USD — a change of 452.15% (higher).

Equity

483,594.00USD

YoY

452.15%

Last updated:

In 2026, Decision Diagnostics's equity was 483,594.00 USD, a 452.15% increase from the 87,584.00 USD equity in the previous year.

Access this data via the Eulerpool API

Decision Diagnostics Stock analysis

What does Decision Diagnostics do? The Decision Diagnostics Corp, founded in 2002, is a company specializing in the manufacturing of medical diagnostic test kits and devices. The company is headquartered in Westlake Village, California, and operates production facilities in various parts of the world. The company's history began when the founders recognized a need for reliable, affordable, and easy-to-use diagnostic devices. This realization led to the development of the first product, the Shasta GenStrip. This test strip allowed patients to monitor their blood sugar levels at home, thereby better managing their diabetes. Since then, Decision Diagnostics Corp has become a leading provider of diagnostic test kits and devices. The company has several divisions, including the pharmaceutical division, the medical division, and the consumables division. In the pharmaceutical division, the company develops and produces tests for the pharmaceutical industry. These tests are used to assess the efficacy of new drugs and detect side effects. The medical division, on the other hand, focuses on developing diagnostic devices for various applications. This includes a test for detecting cancer markers in the blood or a test for assessing vitamin D levels. Another important division of the company is the consumables division. Here, the company provides test strips, syringes, needles, and other materials needed in medical practices and hospitals. The business model of Decision Diagnostics Corp is based on the idea that every person has the right to reliable medical care. Therefore, the company is committed to developing diagnostic devices and test kits that are easy to use and affordable. This allows patients to independently monitor their condition at home and take quick action if necessary. An example of this is the Shasta GenStrip, the first test strip developed by the company. This test strip allows patients to measure their blood sugar at home and better manage their diabetes. The Shasta GenStrip is compatible with common blood glucose meters and is significantly cheaper than comparable products. Another product developed in the medical division is the eScreen. This device allows for quick and reliable testing of urine samples for drugs or alcohol. The eScreen is primarily used in occupational medicine to ensure that employees are not using drugs. Overall, Decision Diagnostics Corp has become an important player in the medical industry. The company strives to provide patients with access to high-quality and affordable diagnostic devices and test kits. Through the constant development of innovative products, the company contributes to improving medical care worldwide. Decision Diagnostics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Decision Diagnostics's Equity

Decision Diagnostics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Decision Diagnostics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Decision Diagnostics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Decision Diagnostics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Decision Diagnostics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Decision Diagnostics stock

The Equity of Decision Diagnostics is 483,594.00 USD in 2026.

The Equity of Decision Diagnostics changed from 87,584.00 USD to 483,594.00 USD, representing a 452.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Decision Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Decision Diagnostics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Decision Diagnostics

All Key Metrics — Decision Diagnostics